Volume 89 Issue 39 | p. 17 | Concentrates
Issue Date: September 26, 2011

Vanderbilt Advances Biotech Partnerships

Department: Business
Keywords: drug discovery, industry-academic partnerships

Vanderbilt University’s Center for Neuroscience Drug Discovery is advancing work with nonacademic partners. Vanderbilt has licensed compounds to Boston-based Karuna Pharmaceuticals for development as potential schizophrenia treatments. Compounds developed under a three-year-old partnership with Seaside Therapeutics of Cambridge, Mass., are now undergoing final preclinical studies as treatments for fragile X syndrome, the most common genetic cause of autism. And a potential Parkinson’s disease treatment developed with the Michael J. Fox Foundation is also advancing toward the clinic.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment